Knight Therapeutics advances chronic GvHD expansion strategy
Chronic GvHD is a serious complication of allogeneic haematopoietic stem cell transplantation (HSCT).
Comment & Opinion
Gender bias in AI health advice: when innovation learns from incomplete data
JPM26: Ypsomed commits to self-care delivery devices in new strategic plan
JPM26: Opus Genetics builds momentum in rare retinal gene therapy
JPM26: Butterfly Network aims to close the global medical imaging gap
JPM26: Rakuten Medical unveils transformative photoimmunotherapy platform
JPM26: ICU Medical hopeful to ‘get out of the woods’ soon
JPM26: Integra resets by fixing supply and riding reimbursement tailwinds
